Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Organon & Co. (NY: OGN ) 20.35 +0.41 (+2.06%) Official Closing Price Updated: 7:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Organon & Co. < Previous 1 2 3 4 5 6 7 8 9 Next > OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024 August 06, 2024 OGN stock results show that Organon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace Organon Reports Results for the Second Quarter Ended June 30, 2024 August 06, 2024 From Organon & Co. Via Business Wire Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount' July 30, 2024 Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot of other stocks." Via Benzinga Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024 July 09, 2024 From Organon & Co. Via Business Wire High Dividend 50: Organon & Co. June 27, 2024 Organon & Co.’s current annual dividend is $1.12 per share. At around $20 per share, Organon stock has a high yield of 5.4%. Via Talk Markets Thursday Is Your Last Chance To Buy Organon Before The Dividend Payout February 20, 2024 Via Benzinga 3 High-Yield Dividend ETFs to Buy to Generate Passive Income July 06, 2024 These exchange-traded funds should keep the income flowing in regularly. Via The Motley Fool Topics ETFs Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now June 26, 2024 Uncover three top value stocks to buy with robust fundamentals for stable long-term growth amid turbulence. Via InvestorPlace 3 Stocks With Mouthwatering Dividends You Can Buy Right Now June 08, 2024 These stocks offer great dividends and more. Via The Motley Fool European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 May 24, 2024 From Organon & Co. Via Business Wire Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields May 10, 2024 Via Benzinga Organon Announces Pricing of $1.0 Billion Senior Notes Offering May 07, 2024 From Organon & Co. Via Business Wire Organon Announces Proposed $1.0 Billion Senior Notes Offering May 07, 2024 From Organon & Co. Via Business Wire Organon Beats On Q1, Women's Health Leads the Charge May 02, 2024 Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared. Via Benzinga OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 OGN stock results show that Organon beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Organon Reports Results for the First Quarter Ended March 31, 2024 May 02, 2024 From Organon & Co. Via Business Wire 7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024 May 01, 2024 While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing. Via InvestorPlace 3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 May 01, 2024 Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. Via InvestorPlace Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024 April 08, 2024 From Organon & Co. Via Business Wire Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints April 08, 2024 From Organon & Co. Via Business Wire Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields March 13, 2024 During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... Via Benzinga Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally March 07, 2024 Here are three top stock picks for rally have their grip in travel, packaged foods, meats and pharmaceuticals. Via InvestorPlace 5 Value Stocks In The Healthcare Sector March 04, 2024 Via Benzinga Drug Maker Organon Stock Scores Relative Strength Upgrade February 28, 2024 In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday. Via Investor's Business Daily Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market February 26, 2024 Explore growth strategies of overlooked stocks with strong fundamentals in strategic investments and market expansion. Via InvestorPlace New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety February 26, 2024 The Attorney General of New York, Letitia James, has called on the FDA to address safety risks associated with the widely used asthma and allergy medicine Singulair (montelukast). Via Benzinga Exposures Product Safety Don't Overlook These Low-Risk High-Dividend Yielding Stocks February 24, 2024 Given the rally in the S&P 500 and the Nasdaq over the last year, it may be wise to consider stocks that should be less volatile during market corrections. Even better is when stocks have dividend... Via Talk Markets Topics Stocks Exposures US Equities First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks February 21, 2024 Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions. Via Benzinga Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary February 20, 2024 From Organon & Co. Via Business Wire Why Is Women Health-Focused Organon Stock Trading Higher On Thursday? February 15, 2024 Organon exceeds Q4 2023 revenue expectations, reaching $1.6 billion. Women's Health thrives with 7% revenue increase, driven by Follistim AQ's 63% growth. Biosimilar revenue surges by 49%. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.